MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - FRESENIUS KABI ONCO.
CADILA HEALTHCARE vs FRESENIUS KABI ONCO. - Comparison Results
CADILA HEALTHCARE Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
FRESENIUS KABI ONCO. 
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
Current Valuations
| CADILA HEALTHCARE | FRESENIUS KABI ONCO. | CADILA HEALTHCARE/ FRESENIUS KABI ONCO. |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 29.9 | 22.1 | 135.1% | View Chart |
| P/BV | x | 4.8 | 3.1 | 154.7% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 CADILA HEALTHCARE  FRESENIUS KABI ONCO. |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-20 |
FRESENIUS KABI ONCO. Mar-13 |
CADILA HEALTHCARE/ FRESENIUS KABI ONCO. |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 352 | 176 | 200.2% | |
| Low | Rs | 207 | 79 | 263.1% | |
| Sales per share (Unadj.) | Rs | 139.2 | 37.7 | 369.4% | |
| Earnings per share (Unadj.) | Rs | 11.8 | 5.1 | 231.0% | |
| Cash flow per share (Unadj.) | Rs | 18.6 | 6.7 | 276.2% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 1.3 | 0 | - | |
| Book value per share (Unadj.) | Rs | 101.4 | 42.5 | 238.2% | |
| Shares outstanding (eoy) | m | 1,023.74 | 158.23 | 647.0% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.0 | 3.4 | 59.4% | |
| Avg P/E ratio | x | 23.7 | 25.0 | 95.1% | |
| P/CF ratio (eoy) | x | 15.0 | 18.9 | 79.5% | |
| Price / Book Value ratio | x | 2.8 | 3.0 | 92.2% | |
| Dividend payout | % | 29.8 | 0 | - | |
| Avg Mkt Cap | Rs m | 286,033 | 20,135 | 1,420.6% | |
| No. of employees | `000 | 13.4 | 1.2 | 1,163.6% | |
| Total wages/salary | Rs m | 24,145 | 703 | 3,433.6% | |
| Avg. sales/employee | Rs Th | 10,632.7 | 5,176.2 | 205.4% | |
| Avg. wages/employee | Rs Th | 1,801.2 | 610.4 | 295.1% | |
| Avg. net profit/employee | Rs Th | 898.5 | 699.6 | 128.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 142,531 | 5,963 | 2,390.3% | |
| Other income | Rs m | 1,139 | 18 | 6,327.8% | |
| Total revenues | Rs m | 143,670 | 5,981 | 2,402.1% | |
| Gross profit | Rs m | 24,198 | 1,430 | 1,692.0% | |
| Depreciation | Rs m | 6,965 | 258 | 2,700.7% | |
| Interest | Rs m | 3,418 | -26 | -13,146.2% | |
| Profit before tax | Rs m | 14,954 | 1,216 | 1,229.6% | |
| Minority Interest | Rs m | 288 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -68 | 0.0% | |
| Tax | Rs m | 3,198 | 342 | 934.5% | |
| Profit after tax | Rs m | 12,044 | 806 | 1,494.5% | |
| Gross profit margin | % | 17.0 | 24.0 | 70.8% | |
| Effective tax rate | % | 21.4 | 28.1 | 76.0% | |
| Net profit margin | % | 8.5 | 13.5 | 62.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 87,154 | 5,102 | 1,708.4% | |
| Current liabilities | Rs m | 82,694 | 2,385 | 3,466.7% | |
| Net working cap to sales | % | 3.1 | 45.6 | 6.9% | |
| Current ratio | x | 1.1 | 2.1 | 49.3% | |
| Inventory Days | Days | 71 | 150 | 47.6% | |
| Debtors Days | Days | 94 | 113 | 82.8% | |
| Net fixed assets | Rs m | 133,236 | 5,148 | 2,588.1% | |
| Share capital | Rs m | 1,024 | 158 | 647.3% | |
| "Free" reserves | Rs m | 102,733 | 6,556 | 1,567.1% | |
| Net worth | Rs m | 103,757 | 6,732 | 1,541.3% | |
| Long term debt | Rs m | 32,146 | 952 | 3,376.0% | |
| Total assets | Rs m | 236,866 | 10,388 | 2,280.2% | |
| Interest coverage | x | 5.4 | -45.8 | -11.7% | |
| Debt to equity ratio | x | 0.3 | 0.1 | 219.0% | |
| Sales to assets ratio | x | 0.6 | 0.6 | 104.8% | |
| Return on assets | % | 6.5 | 7.5 | 86.9% | |
| Return on equity | % | 11.6 | 12.0 | 97.0% | |
| Return on capital | % | 13.7 | 14.6 | 94.0% | |
| Exports to sales | % | 0 | 74.5 | 0.0% | |
| Imports to sales | % | 0 | 24.8 | 0.0% | |
| Exports (fob) | Rs m | NA | 4,441 | 0.0% | |
| Imports (cif) | Rs m | NA | 1,477 | 0.0% | |
| Fx inflow | Rs m | 52,752 | 5,298 | 995.8% | |
| Fx outflow | Rs m | 14,504 | 1,772 | 818.4% | |
| Net fx | Rs m | 38,248 | 3,525 | 1,084.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 25,054 | 1,274 | 1,966.4% | |
| From Investments | Rs m | -10,123 | -1,204 | 840.6% | |
| From Financial Activity | Rs m | -10,942 | -196 | 5,579.8% | |
| Net Cashflow | Rs m | 3,989 | -126 | -3,158.4% | |
Share Holding
| Indian Promoters | % | 74.8 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 81.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 0.3 | 2,766.7% | |
| FIIs | % | 5.9 | 9.6 | 61.5% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 11.0 | 9.1 | 120.9% | |
| Shareholders | 44,069 | 42,599 | 103.5% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: SANOFI INDIA ABBOTT INDIA STRIDES PHARMA SCIENCE CIPLA TORRENT PHARMA
Compare CADILA HEALTHCARE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Momentum Moves: The Week Gone By(Momentum Moves)
Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.
Related Views on News
CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)
Oct 26, 2020 | Updated on Oct 26, 2020Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)
Aug 21, 2020 | Updated on Aug 21, 2020For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)
Jan 5, 2021My new guide will show you the huge potential in future proof businesses.
'Essential' Smallcap Stock Recommendations(Profit Hunter)
Jan 8, 2021The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
Is Nifty Forming a Top(Fast Profits Daily)
Jan 8, 2021The charts are telling the bulls to be cautious.
Why Gold Hit Lower Circuit(Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Five Wishes and a Will(The Honest Truth)
Jan 4, 2021Ajit Dayal on the investing strategy for 2021 and beyond.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
CADILA HEALTHCARE SHARE PRICE
Jan 15, 2021 (Close)
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE 8-QTR ANALYSIS
COMPARE CADILA HEALTHCARE WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.